We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Lorus Therapeutics Announces Publication on LOR-2040 Anticancer Activity in Acute Myeloid Leukemia

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "Lorus Therapeutics Announces Publication on LOR-2040 Anticancer Activity in Acute Myeloid Leukemia"

Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Lorus Therapeutics Inc., has announced the publication of a research article by investigators at Ohio State University (OSU) demonstrating that Lorus' lead cancer drug LOR-2040, formerly known as GTI-2040, improves the anticancer effects of the chemotherapy drug Ara-C.

The lead authors of the publication were Dr Ping Chen and Dr Josephine Aimiuwu who carried out these studies in the laboratories of Dr Guido Marcucci and Dr Kenneth Chan at OSU. The results in the article provide support for continuing the clinical program of LOR-2040 in combination with Ara-C in the treatment of relapsed and refractory acute myeloid leukemia (AML).

In the article, OSU investigators found that LOR-2040 significantly increased the antiproliferative activity of Ara-C in leukemia cells as a result of downregulation of the LOR-2040 target, R2. Treatment of leukemia cells with LOR-2040 plus Ara-C resulted in the production of higher intracellular amounts of Ara-CTP, which is the cytotoxic product of Ara-C, than was possible with Ara-C alone.

The study also provided support for the intracellular mechanism through which this increased anti-tumor activity is achieved. LOR-2040 additionally showed a dose-dependent accumulation in leukemia cells that correlated with decreased levels of R2. The study investigators concluded that the data provided a mechanistic justification for evaluation of LOR-2040 in combination with Ara-C in AML patients.

"The findings in this publication are important because they demonstrate that LOR-2040 and Ara-C have synergistic anticancer effects in leukemia", said Dr. Aiping Young, Lorus' President and CEO. "Although Ara-C is effective in the treatment of relapsed and refractory AML, there is a need for safe and effective additional therapies to be used in combination with Ara-C to increase the rate of cancer remissions and patient survival. This article gives us further validation of the potential of LOR-2040 as an efficacious treatment for this disease."

The article entitled "Biochemical Modulation of Aracytidine (Ara-C) Effects by GTI-2040, a Ribonucleotide Reductase Inhibitor, in K562 Human Leukemia Cells" was published in the peer-reviewed journal The AAPS Journal and is available on the Journal's website.